AlphAIalphai — Financial news for AI agents
rttnews.comSEP 32 min read$MIST

Milestone Gets China Approval For Etripamil Nasal Spray

Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.

Original reporting
rttnews.com
Published Sep 3, 2026, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone Gets China Approval For Etripamil Nasal Spray — source image
Source · rttnews.com
Decision brief

The 30-second read

$MISTBullishHigh
01

Why it matters

The approval unlocks a $2M milestone and up to $98M in future payments, providing immediate cash and long‑term royalty upside.

02

Market read

Regulatory clearance in China is a material catalyst for Milestone, likely driving short‑term stock appreciation and long‑term revenue growth.

03

What to watch

Potential competition from local Chinese manufacturers and regulatory scrutiny on pricing.

Relevance 8/10Novelty 8/10Timing: today

Background

Milestone's etripamil (CARDAMYST) is the first US‑approved nasal spray for PSVT; the China approval expands its geographic footprint.

Company-level read

Ticker impact

$MISTBullishHigh confidence
Context

Milestone Pharmaceuticals received China NMRA approval for its etripamil nasal spray, triggering a $2M milestone payment and eligibility for up to $98M in future milestones.

Expected impact

Expect short‑term upside as investors price in Chinese market entry and future royalty streams.

Evidence & confidence

First‑report approval, sizable upside from China sales, and immediate cash milestone create a clear catalyst.

Market effects

Sector

Other cardiac arrhythmia drug developers may see heightened interest in Asian regulatory pathways.

Regional

Adds to the pipeline of US biotech firms entering the Chinese market, supporting sector growth in China.

Global

Highlights growing cross‑border collaborations and could influence investor sentiment toward US‑listed biotech stocks.

Counterpoint

What could challenge this read

Milestone's commercial success depends on pricing and reimbursement in China, which remain uncertain.

Key entities

  • Company
    Milestone Pharmaceuticals

    US biotech developing etripamil nasal spray.

  • Company
    Everest Medicines

    Licensee for etripamil in Greater China.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 21
$MISTMed

Milestone Pharmaceuticals stock gains on Phase 3 AFib trial

Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor

investing.com2 min
AUG 19
$MISTMed

Milestone (MIST) Q2 2026 Earnings Call Transcript

Milestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.

fool.com3 min
AUG 13
$MISTMed

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.

yahoo.com6 min
AUG 12
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

finanznachrichten.de7 min
Milestone Gets China Approval For Etripamil Nasal Spray — alphai